Biopharma Talent Hunt: Top C-suite Recruiter Mulls The Next Generation Of Leaders
An interview with Odgers Berndtson's John Hawkins about the credentials needed for the next-gen biopharma C-suite. A supplement to our feature on the In Vivo/EBD Academy survey, “Future-Proofing Human Capital: Does Biopharma Have the Right Stuff?”
You may also be interested in...
In this supplement to our feature on the In Vivo/EBD Academy survey "Future-Proofing Human Capital In Global Life Sciences", Ramona Sequeira, President of Takeda Pharmaceutical's US Business Unit, presents her company’s strategy to anticipate and respond to a disruptive transformation of the industry payer base.
Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.
Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.